Press Releases Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange Other stock markets 11:30:41 2024-05-31 am EDT			5-day change	1st Jan Change
93.17 ^CHF	+2.13%		+1.56%	+9.78%

May. 31	NOVARTIS AG : UBS reiterates its Buy rating	ZD
May. 31	European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease	May. 31	PU
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML	May. 31	GL
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	May. 30	GL
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	May. 25	GL
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo	May. 25	GL
Amgen And Sandoz Settle Denosumab BPCIA Litigation	May. 20	AQ
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash	May. 16	GL
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA	May. 15	GL
Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML	May. 13	AQ
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update	May. 10	AQ
Novartis : enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline	May. 02	PU
Novartis : Q1 2024 impact and sustainability update	Apr. 30	PU
European Commission authorises one of first ustekinumab biosimilars in Europe	Apr. 26	AQ
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria	Apr. 24	GL
Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024	Apr. 23	AQ
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	GL
Novartis: Q1 Earnings Snapshot	Apr. 23	AQ
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised	Apr. 23	GL
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	Apr. 17	GL
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)	Apr. 15	GL